FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月7日 第 1 頁 共 12 頁 v 1.3.0 | 1). | 購回股份(或其他證券)但沒有註銷 | 302,500 | 0.01 % | RMB | 66.14 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年6月26日，本公司實施2025年以集中競價交易方式回購本公司 | | | | | | | A股股份方案（"2025年第一次回購"），并回購302,500股A股股份。 | | | | | | | 變動日期 2025年6月26日 | | | | | | 2). | 購回股份(或其他證券)但沒有註銷 | 303,367 | | | | | | | | 0.01 % ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司 法權區內刊發或派發。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券的邀請或要約。 本公告並非，亦不構成於美國（定義見1933年《美國證券法》（「《證券法》」）S規例）出售證券的 要約或邀請及其任何部分。本公告或其任何內容或其副本亦不得攜進美國境內或於美國境內 或在刊發或派發本公告屬違法的任何其他司法權區內直接或間接派發。除非本公告所指證券 根據《證券法》辦理登記或獲豁免遵守《證券法》的登記規定，否則有關證券未曾亦不會根據《證 券法》登記，且不得在美國境內提呈發售、出售或以其他方式轉讓。本公司並無計劃在美國 登記本公告所述任何證券或在美國公開發售任何證券。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 根據一般授權完成 ...

沪指8月7日上涨0.16%，申万所属行业中，今日上涨的有18个，涨幅居前的行业为有色金属、美容护 理，涨幅分别为1.20%、0.99%。跌幅居前的行业为医药生物、电力设备，跌幅分别为0.92%、0.74%。 医药生物行业位居今日跌幅榜首位。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 688166 | 博瑞医药 | -5.70 | 3.89 | 23275.85 | | 002173 | 创新医疗 | 10.01 | 30.10 | 22618.18 | | 000710 | 贝瑞基因 | 5.26 | 23.64 | 20015.67 | | 300289 | 利德曼 | 20.02 | 21.71 | 17141.65 | | 002022 | 科华生物 | 9.96 | 12.63 | 15290.70 | | 300981 | 中红医疗 | 19.99 | 8.06 | 11833.89 | | 300760 | 迈瑞医疗 | 1.09 | 0.60 | 11395.45 | | 00 ...

截至8月7日收盘，创新药概念下跌1.41%，位居概念板块跌幅榜前列，板块内，千红制药跌停，华海药 业、亚太药业、康弘药业等跌幅居前，股价上涨的有36只，涨幅居前的有润都股份、海辰药业、粤万年 青等，分别上涨9.98%、7.22%、6.19%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 稀土永磁 | 3.24 | 减肥药 | -1.70 | | 脑机接口 | 2.69 | CRO概念 | -1.66 | | 高压氧舱 | 2.56 | 创新药 | -1.41 | | 太赫兹 | 1.65 | 仿制药一致性评价 | -1.34 | | 血氧仪 | 1.62 | 重组蛋白 | -1.29 | | 存储芯片 | 1.40 | 中船系 | -1.28 | | MCU芯片 | 1.18 | 阿尔茨海默概念 | -1.18 | | 无线耳机 | 1.08 | 特钢概念 | -1.02 | | 汽车芯片 | 1.02 | 细胞免疫治疗 | -1.02 | | DRG/DIP | 1.00 | PET铜箔 | -0.99 ...

| 603538 | 美诺华 | -5.28 | 13.44 | -7141.76 | | --- | --- | --- | --- | --- | | 000953 | 河化股份 | 1.00 | 21.58 | -6783.63 | | 688222 | 成都先导 | -3.49 | 6.59 | -6676.58 | | 300363 | 博腾股份 | -1.62 | 4.18 | -6054.08 | | 600196 | 复星医药 | -0.98 | 1.29 | -5749.1 1 | | 688185 | 康希诺 | -2.80 | 5.15 | -5649.33 | | 688131 | 皓元医药 | -2.95 | 3.76 | -5426.18 | | 300683 | 海特生物 | -3.97 | 13.76 | -5362.08 | | 688553 | 汇宇制药 | -1.87 | 2.83 | -5128.77 | | 301096 | 百诚医药 | -2.81 | 6.89 | -4796.39 | | 300149 | 睿智医药 | -1.65 | 8.06 | -3859. ...

Core Viewpoint - On August 7, securities firms issued "buy" ratings for over 20 A-share listed companies, focusing on sectors such as medical services, agriculture, home appliances, semiconductors, construction materials, fertilizers, and specialized equipment [1]. Group 1: Key Stocks Recommended by Securities Firms - WuXi AppTec (603259) received a "buy" rating from Zhongyou Securities, with an upward revision of its annual performance guidance, expecting revenues of 43.29 billion, 49.02 billion, and 55.85 billion yuan for 2025, 2026, and 2027, respectively, with a net profit of 14.91 billion, 13.88 billion, and 16.16 billion yuan [2][3]. - Zhong'an Shares (002891) was highlighted by Kaiyuan Securities for significant revenue and profit growth, with a focus on domestic sales [2]. - Haida Group (002311) is noted for its overseas expansion potential, with a report from Guoxin Securities emphasizing its status as a quality asset in the agriculture sector [3][4]. - Junshi Network (688475) was rated "buy" by Yuanyin Galaxy, citing strong growth in its smart home business [2]. - Chipone Technology (688521) showed improved profitability in Q2, with a report from Xinda Securities [2]. - Dongfang Yuhong (002271) is expected to reach a profitability turning point in the second half of the year, according to Zhongyou Securities [2]. - Haiguang Information (688041) received attention for its performance in the semiconductor sector [2]. - Cangge Mining (000408) was noted for stable profitability in potassium chloride and strong performance from its copper mine [2]. - Jereh Group (002353) reported a 37% year-on-year increase in net profit, exceeding expectations [2]. - Zhuozhao Dispensing (873726) received initial coverage for its diverse expansion in dispensing equipment [2]. Group 2: Overall Market Insights - The focus of securities firms on various sectors indicates a strategic interest in industries with growth potential, particularly in medical services and agriculture [1][4]. - The reports suggest that while "buy" or "increase" ratings are provided, they do not guarantee stock price increases, and investors should consider these ratings as references rather than definitive investment advice [4].

Group 1 - The core viewpoint of the report is that Zhongyou Securities has given WuXi AppTec (603259.SH, latest price: 91.13 yuan) a buy rating due to its strong business performance [2] - The Chemistry business revenue continues to grow rapidly, while the Testing business revenue has stabilized [2] - The company has maintained a rapid growth in its order backlog and has raised its full-year revenue guidance [2]

Core Viewpoint - WuXi AppTec's profitability is steadily improving, leading to an upward revision of its full-year performance guidance [1] Financial Performance - In the first half of 2025, the company achieved operating revenue of 20.8 billion yuan (+20.6% year-on-year), with continuous operating business revenue at 20.41 billion yuan (+24.2% year-on-year) [1] - The net profit attributable to shareholders reached 8.56 billion yuan (+101.9%), while the adjusted Non-IFRS net profit was 6.31 billion yuan (+44.4%) [1] - For Q2 2025, operating revenue was 11.15 billion yuan (+20.4%), with continuous operating business revenue at 11.02 billion yuan (+24.9%) [1] Business Segment Analysis - Chemistry business revenue for the first half of 2025 was 16.3 billion yuan (+33.5%), with an adjusted Non-IFRS gross margin of 49.0% (+5.2 percentage points) [2] - The TIDES business saw significant growth, with revenue of 5.03 billion yuan (+141.6%) in the first half of 2025, and a backlog of orders increasing by 48.8% year-on-year [2] - The Testing business revenue decreased slightly to 2.69 billion yuan (-1.2%), with a decline in adjusted Non-IFRS gross margin to 25.1% [3] Order Backlog and Guidance - As of June 30, 2025, the company had a continuous operating business backlog of 56.69 billion yuan (+37.2%) [4] - The full-year revenue growth guidance for 2025 has been revised to 13%-17%, up from the previous 10%-15% [4] Profit Forecast and Investment Recommendation - Revenue projections for 2025, 2026, and 2027 are 43.29 billion yuan, 49.02 billion yuan, and 55.85 billion yuan, respectively, with year-on-year growth rates of 10.3%, 13.3%, and 13.9% [5] - The company is rated as a "buy" due to its leading position in the integrated drug development service platform and the expected recovery in its core Chemistry business [5]

Core Viewpoint - The article highlights the significant outflow of capital from various stocks, indicating potential concerns among investors regarding these companies' performance and market sentiment [1]. Group 1: Major Stocks with Capital Outflow - China Shipbuilding Industry Corporation experienced a capital outflow of 1.074 billion [1] - Zhongji Xuchuang saw a capital outflow of 783 million [1] - China State Shipbuilding Corporation had a capital outflow of 749 million [1] - Xinyi Technology faced a capital outflow of 711 million [1] - Changcheng Military Industry experienced a capital outflow of 645 million [1] - WuXi AppTec had a capital outflow of 639 million [1] - Shanhe Intelligent saw a capital outflow of 630 million [1] - Shenghong Technology experienced a capital outflow of 529 million [1] - Inner Mongolia First Machinery Group had a capital outflow of 522 million [1] - Oriental Communications faced a capital outflow of 460 million [1] - Northern Rare Earth experienced a capital outflow of 459 million [1] - Heng Rui Medicine had a capital outflow of 388 million [1] - Robot Group saw a capital outflow of 377 million [1] - Shaanxi Coal and Chemical Industry experienced a capital outflow of 347 million [1] - Huadian Electric had a capital outflow of 344 million [1] - Huagong Technology faced a capital outflow of 327 million [1] - Hunan Tianyan experienced a capital outflow of 325 million [1] - Inovance Technology had a capital outflow of 309 million [1] - Magmi Technology faced a capital outflow of 297 million [1] - Beijia Clean experienced a capital outflow of 274 million [1]

Group 1 - The main focus of the article is on the significant outflow of capital from the top 20 stocks as of August 7, with notable amounts withdrawn from various companies [1][2] - China Shipbuilding Industry Corporation (中国重工) experienced the highest capital outflow at 1 billion yuan, followed by Zhongji Xuchuang (中际旭创) with 722 million yuan [1] - Other companies with substantial capital outflows include Xinyi Technology (新易盛) at 661 million yuan, China Shipbuilding (中国船舶) at 614 million yuan, and WuXi AppTec (药明康德) at 593 million yuan [1] Group 2 - The list of companies with the largest capital outflows also includes Changcheng Military Industry (长城军工) at 510 million yuan and Shenghong Technology (胜宏科技) at 506 million yuan [1] - Northern Rare Earth (北方稀土) saw an outflow of 476 million yuan, while Inner Mongolia First Machinery Group (内蒙一机) had 461 million yuan [1] - Other notable companies with significant outflows include Shanhe Intelligent (山河智能) at 441 million yuan and Dongfang Precision (东方精工) at 439 million yuan [1]